# EDGAR Filing Document

**Accession Number:** 0001421876
**File Stem:** 0001171843-26-000943
**Filing Date:** 2026-2
**Character Count:** 7632
**Document Hash:** f362010188dfa6933ff2470c81fdadf4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-000943.hdr.sgml**: 20260219

**ACCESSION NUMBER**: 0001171843-26-000943

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260219

**FILED AS OF DATE**: 20260219

**DATE AS OF CHANGE**: 20260219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GALAPAGOS NV
- **CENTRAL INDEX KEY:** 0001421876
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37384
- **FILM NUMBER:** 26655190

**BUSINESS ADDRESS:**
- **STREET 1:** GEN DE WITTELAAN L11 A3
- **CITY:** 2800 MECHELEN
- **STATE:** C9
- **ZIP:** 00000
- **BUSINESS PHONE:** 3215342900

**MAIL ADDRESS:**
- **STREET 1:** GEN DE WITTELAAN L11 A3
- **CITY:** 2800 MECHELEN
- **STATE:** C9
- **ZIP:** 00000

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2026**

Commission File Number: **001-37384**

**GALAPAGOS NV**

(Translation of registrant's name into English)

**Generaal De Wittelaan L11 A3 2800 Mechelen, Belgium**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, except for the quotes of Jérôme Contamine and Henry Gosebruch, included in Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

------

On February 19, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[Exhibit 99.1. Press release dated February 19, 2026](exh_991.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>**&nbsp;&nbsp;&nbsp;&nbsp;GALAPAGOS NV&nbsp;&nbsp;&nbsp;&nbsp;**</u> |
|  | (Registrant) |
| Date: February 19, 2026 | <u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Annelies Denecker&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Annelies Denecker |
|  | Company Secretary |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors** 

***Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board***

**Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG), today announced the appointment by way of co-optation of Dr. Paulo Fontoura as Non-Executive Independent Director to its Board of Directors, effective February 9, 2026.**

"We are pleased to welcome Paulo to our Board," said Jérôme Contamine, Chair of the Board of Galapagos. "His global leadership experience, deep understanding of clinical development strategy, and proven track record of assessing and advancing differentiated assets will strengthen the Board's ability to provide strategic guidance as the Company evaluates transformative business development opportunities." Dr. Paulo Fontoura replaces Dr. Susanne Schaffert, who stepped down from the Board effective November 1, 2025, as previously announced in the press release dated October 30, 2025.

"Galapagos is entering its next phase with a clear strategic focus and commitment to disciplined growth," said Henry Gosebruch, CEO of Galapagos. "I look forward to continuing to work alongside our accomplished Board and senior leadership team and to welcoming Paulo as we execute our strategy to advance innovative medicines for patients and deliver long-term value for shareholders."

**Biography**

Dr. Paulo Fontoura brings 20 years of pharmaceutical industry experience, with deep expertise in neurology, immunology, ophthalmology, and rare diseases. He currently serves as Chief Medical Officer at Xaira. Before joining Xaira, Dr. Fontoura was SVP and Global Head at Roche, where he led clinical development across neuroscience, immunology, ophthalmology, and rare diseases, contributed to the launch of multiple breakthrough therapies, and pioneered digital health approaches, such as smartphone-based clinical endpoints. He previously held academic roles at the New University of Lisbon, where he earned his MD and PhD in Neuroimmunology. Dr. Fontoura also completed a postdoctoral fellowship at Stanford University, is a Fellow of the American Academy of Neurology, and continues to teach as a visiting professor in Lisbon and as a lecturer in Basel.

**For further information, contact Galapagos:**

**Investor Relations**

Glenn Schulman

+1 412 522 6239

ir@glpg.com

**Media**

Media

Katie Morris

+1 952 288 6821

katiemorris@ententeinc.com

Visit us at www.glpg.com or follow us on LinkedIn or X.

**Forward-looking statements**

*This press release may include forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "will," "long-term," and "forward," and any similar expressions. These statements include, but are not limited to, statements regarding the appointment by way of co-optation of a new director, our business development and associated transformative opportunities, the expected benefits associated with the changes to our Board, the Board's ability to provide strategic guidance, the advancement of our innovative medicines for patients, and our ability to deliver long-term value for shareholders. Any forward-looking statements in this press release are based on our management's current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve unknown and known risks, uncertainties, and other factors which might cause our actual results, performance, or achievements to be materially different from any historic or future results, performance, or achievements expressed or implied by such statements. These risks, uncertainties, and other factors include, without limitation, the risk that we may not be able to realize the expected benefits from the appointment of the new director. A further list and description of these risks, uncertainties, and other factors can be found in our filings and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20-F filed with the SEC, as supplemented and/or modified by any other filings and reports that we have made or will make with the SEC in the future. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if our results, performance, or achievements are consistent with such forward-looking statements, they may not be predictive of results, performance, or achievements in future periods. These forward-looking statements speak only as of the date of publication of this press release. We expressly disclaim any obligation to update any forward-looking statements in this press release, unless required by law or regulation.*